ClinicalTrials.gg
CompletedNCT02320487Updated Feb 11, 2020Results posted

A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

A Phase 2 interventional study of Bendamustine and Obinutuzumab in Chronic Lymphocytic Leukemia, sponsored by Genentech, Inc.. Completed at 26 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-11.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing bendamustine in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 3 under way, 1 of them phase 3. bendamustine · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
7th of 46
102 · median 35
Started
2015
with 2 others
Phase 2
22 of 46
1 open now
Registered
38th of 46
by date
Lead sponsor
2 of 46
Genentech, Inc.

Among the 46 studies testing bendamustine in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 7th largest by enrollment, is one of 3 that started in 2015, is one of 22 in phase 2, and was the 38th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

1 of the 46 studies testing bendamustine in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About bendamustine

bendamustine: first FDA approval 2008 (TREANDA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing bendamustine in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This is a Phase 2, open-label, multicenter study to evaluate the safety and efficacy of BG induction therapy in participants with previously untreated CLL. The anticipated time on study treatment is 24 weeks.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must satisfy one of the criteria for treatment initiation, as outlined in the iwCLL NCI-WG guidelines. The criteria include: (a) Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia, (b) Massive (i.e., greater than or equal to [>=] 6 centimeters [cm] below the left costal margin) or progressive or symptomatic splenomegaly, (c) Massive nodes (i.e., >= 10 cm in longest diameter) or progressive or symptomatic lymphadenopathy, (d) Progressive lymphocytosis with an increase of greater than (>) 50 percent (%) over a 2-month period or lymphocyte doubling time (LDT) of less than (\<) 6 months, (e) anemia and/or thrombocytopenia that is poorly responsive to or other standard therapy, (f) Constitutional symptoms, defined as any one or more of the following disease-related symptoms or signs: unintentional weight loss of >=10% within the previous 6 months, significant fatigue (i.e., Performance Status [ECOG PS] of 2 or worse or the inability to work or perform usual activities), fevers higher than 100.5 degrees Fahrenheit (°F)/38.0 degrees Celsius (°C) for >= 2 weeks without other evidence of infection, or night sweats for >1 month without evidence of infection
  • (ANC) >=1.5 × 10\^9 per liter (/L) and >=75 × 10\^9/L unless cytopenia is caused by the underlying disease, i.e., no evidence of additional bone marrow dysfunction (e.g., myelodysplastic syndrome, hypoplastic bone marrow)
  • >6 months
  • ECOG PS of 0, 1, or 2
  • Willing to use acceptable measures as defined by the protocol during and at least for 6 months (male participants) or 12 months (female participants) after the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating, or intending to become pregnant during the study: Women who are not (>=12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 14 days prior to initiation of study drug
  • Participants who have received previous CLL therapy, including therapies
  • Transformation of CLL to aggressive non-Hodgkin's lymphoma (Richter's transformation)
  • Inadequate renal function
  • Inadequate liver function: National Cancer Institute (NCI CTCAE) Grade 3 liver function tests ( [AST] or alanine aminotransferase [ALT] >5× [ULN] for >2 weeks; >3× ULN) unless due to underlying disease
  • History of other , which could affect compliance with the protocol or interpretation of results
  • Participants with active bacterial, viral, or fungal infection requiring systemic treatment
  • Participants with known infection with (HIV) or human T-cell leukemia virus 1 (HTLV-1)
  • Positive hepatitis serology: (a) Participants with positive serology for , defined as positivity for hepatitis B surface antigen (HBsAg), or participants who are HBsAg negative but are hepatitis B core antibody (anti-HBc) positive, (b) Participants positive for anti-HBc, but with negative hepatitis B Virus (HBV) deoxyribonucleic acid (DNA), will be considered for inclusion by the Medical Monitor on a case-by-case basis in order to ensure feasibility of monthly DNA testing and availability of appropriate care in case of hepatitis B reactivation, (c) Participants with positive serology for (HCV) unless HCV (by ribonucleic acid [RNA]) is confirmed negative
  • History of severe allergic or anaphylactic reactions to monoclonal antibodies
  • Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease (such as Class III or IV cardiac disease, myocardial infarction within the previous 6 months, unstable arrhythmias, or unstable angina) or pulmonary disease (including obstructive pulmonary disease and history of symptomatic bronchospasm)
  • Vaccination with a a minimum of 30 days prior to study treatment
  • Use of investigational agents of any kind within 30 days before study treatment
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Obinutuzumab + Bendamustine (BG)

    Participants received obinutuzumab + bendamustine (BG) induction therapy in 28-day cycles for 6 cycles.

    Drug: Bendamustine · Drug: Obinutuzumab

Interventions

  • Bendamustine was administered as an intravenous infusion at a dose of 90 milligrams per square meter (mg/m\^2) on Days 2 and 3 Cycle 1; and on Days 1 and 2 Cycles 2-6.

    Also known as: Treanda, Levact

  • Obinutuzumab was administered as an intravenous infusion at a dose of 100 milligrams (mg) on Day 1 Cycle 1; at a dose of 900 mg on Day 2 Cycle 1; at a dose of 1000 mg on Days 8 and 15 Cycle 1, and Day 1 Cycles 2-6.

    Also known as: GA101, Gazyva™, RO5072759

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Complete Response (CR), as Determined by the Investigator Using International Workshop on Chronic Lymphocytic Leukemia National Cancer Institute-Working Group (iwCLL NCI-WG) Guidelines

    The CR rate was defined as CR or CR with incomplete blood count recovery (CRi), assessed by the investigator according to iwCLL NCI-WG criteria. The definition of confirmed CR required all of the following criteria as assessed at least 2 months after completion of therapy: peripheral blood lymphocytes \< 4 times 10\^9 cells/L; absence of significant lymphadenopathy, hepatomegaly, or splenomegaly due to CLL involvement; absence of constitutional symptoms; normal complete blood count (CBC) without need for transfusion or exogenous growth factors, as exhibited by neutrophils \>/= 1.5 times 10\^9 cells/L, platelets \> 100 times 10\^9 cells/L, and hemoglobin \> 11.0 g/dL; normocellular BM aspirate with \< 30% lymphocytes; absence of lymphoid nodules; and BM biopsy without CLL activity. Those fulfilling CR criteria but who have persistent anemia, thrombocytopenia, or neutropenia were considered CRi.

    Time frame: 2 to 3 months after the last infusion of study treatment (up to approximately 228 to 258 days)

Secondary outcomes

  1. Percentage of Participants With Objective Response of CR or Partial Response (PR) at the End of Induction Therapy, as Determined by the Investigator Using iwCLL NCI-WG Guidelines

    CR is defined in the previous outcome measure. The definition of PR required that the following be documented for minimum 2 months: \>/= 50% decrease in peripheral blood lymphocytes from Baseline; reduction in lymphadenopathy; \>/= 50% reduction in spleen or liver enlargement; and CBC with one of the following without need for transfusion or exogenous growth factors: polymorphonuclear leukocytes \>/= 1.5 times 10\^9 cells/L, platelets \> 100 times 10\^9 cells/L or \>/= 50% improvement from Baseline, or hemoglobin \> 11.0 g/dL or \>/= 50% improvement from Baseline.

    Time frame: 2 to 3 months after the last infusion of study treatment (up to approximately 228 to 258 days)

  2. Duration of Response Among Participants With Objective Response of CR or PR, as Determined by the Investigator Using iwCLL NCI-WG Guidelines

    Duration of response was defined as the time from the first assessment of CR, CRi, PR, or nodular partial response (nPR) to the first documentation of PD or death, whichever occurred first. CR, CRi, and PR are identified in previous outcome measures. Participants with lymphoid nodules who otherwise met CR criteria were considered nPR. Participants with post-baseline response assessments (excluding progressive disease) but with no end-of-induction treatment response available were censored on Day 1, and those with end-of-induction treatment response available but who did not experience death or disease progression before the end of the study were censored on the day of the last available assessment.

    Time frame: From the first assessment of CR, CRi, PR, or nPR (at up to approximately 228 to 258 days) until disease progression, relapse, or death from any cause, whichever occurred first (up to 46 months)

  3. Progression-Free Survival (PFS), as Determined by the Investigator Using iwCLL NCI-WG Guidelines

    PFS was defined as the time from the start of induction treatment (Day 1) to the first occurrence of disease progression, relapse as determined by the investigator using iwCLL NCI WG guidelines, or death (within 28 days after the last dose of study drug), whichever occurred first. Disease progression: at least one of the following: lymphadenopathy; increase in the liver or spleen size by 50% or more or the appearance of hepatomegaly or splenomegaly; an increase in the number of blood lymphocytes by 50% or more with at least 5000 B lymphocytes per microliter; transformation to a more aggressive histology; occurrence of cytopenia (neutropenia, anemia, or thrombocytopenia) attributable to CLL. Relapse: Having achieved CR or PR, but after a period of 6 or more months, having demonstrated evidence of disease progression. Participants who did not experience death or disease progression before the end of the study were censored on the day of the last available assessment.

    Time frame: Day 1 until disease progression, relapse, or death from any cause, whichever occurred first (up to 46 months)

  4. Overall Survival (OS)

    OS was defined as the time from the start of induction treatment to death from any cause. Participants who did not experience death or disease progression before the end of the study were censored on the day of the last available assessment.

    Time frame: Day 1 until death from any cause (up to 46 months)

  5. Percentage of Participants Who Achieved Minimal Residual Disease (MRD)-Negative Status in Bone Marrow at Any Time During the Study

    MRD was assessed by 4-color flow cytometry, using iwCLL criteria for MRD negativity (\<1 CLL cell detected in 10,000 leukocytes) in bone marrow aspirate. Flow cytometry provides rapid analysis of multiple characteristics of single cells by using light to count and profile cells in a fluid mixture.

    Time frame: Up to 46 months

  6. Percentage of Participants Who Achieved MRD-Negative Status in Peripheral Blood at Any Time During the Study

    MRD was assessed by 4-color flow cytometry, using iwCLL criteria for MRD negativity (\<1 CLL cell detected in 10,000 leukocytes) in peripheral blood. Flow cytometry provides rapid analysis of multiple characteristics of single cells by using light to count and profile cells in a fluid mixture.

    Time frame: Baseline up to 46 months

  7. Time to MRD-Negative Status in Peripheral Blood

    MRD was assessed by 4-color flow cytometry, using iwCLL criteria for MRD negativity if the value is \<10\^-4 (\<1 CLL cell detected in 10,000 leukocytes) in peripheral blood. Flow cytometry provides rapid analysis of multiple characteristics of single cells by using light to count and profile cells in a fluid mixture. Time to MRD-negative status is defined as the time between MRD positivity (\>= 10\^-4) or the time of first dose treatment for patients who were missing MRD status assessment at baseline to the first achievement of MRD negativity in the peripheral blood.

    Time frame: Baseline up to 46 months

  8. Duration of MRD-Negativity in Peripheral Blood Among Participants Who Achieved MRD-Negative Status

    MRD was assessed by 4-color flow cytometry, using iwCLL criteria for MRD negativity (\<1 CLL cell detected in 10,000 leukocytes) in peripheral blood. Flow cytometry provides rapid analysis of multiple characteristics of single cells by using light to count and profile cells in a fluid mixture. Duration of MRD-negativity among patients who achieved MRD negativity in the study is defined as the period between the first occurrence of MRD-negative status and a subsequent MRD-positive status.

    Time frame: Baseline up to 46 months

  9. Minimum Observed Concentration (Ctrough) of Obinutuzumab After Cycle 2

    Ctrough is the measured concentration of a drug at the end of a dosing interval at steady state.

    Time frame: Pre-infusion (0 hours) on Day 1 Cycle 3 (1 cycle = 28 days)

  10. Ctrough of Obinutuzumab After Cycle 4

    Ctrough is the measured concentration of a drug at the end of a dosing interval at steady state.

    Time frame: Pre-infusion (0 hours) on Day 1 Cycle 5 (1 cycle = 28 days)

  11. Change From Baseline in the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score

    The EORTC QLQ-C30 included global health status, functional scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea/vomiting, and pain) and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Most questions used a 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores were averaged and transformed to 0 - 100 scale, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be a minimally important difference to participants. A positive change from Day 1, Cycle 1 (baseline) indicates improvement. EOT=end of treatment.

    Time frame: Day 1 Cycles 1 (baseline), 3, 6; end of treatment, 2 months after last dose, every 3 months thereafter for 2 years (up to 46 months) (1 cycle = 28 days)

  12. Change From Baseline in the EORTC Quality of Life Questionnaire-Chronic Lymphocytic Leukemia 16 (QLQ-CLL16) Score

    The EORTC Quality of Life Questionnaire-Chronic Lymphocytic Leukemia 16 (QLQ-CLL16) module included assessments of fatigue, treatment side effects, disease symptoms, infection, social activities, and future health worries. Final scores are transformed such that they range from 0 - 100, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be a minimally important difference to participants. A positive change from Day 1, Cycle 1 (baseline) indicates improvement. EOT=end of treatment.

    Time frame: Day 1 Cycles 1 (baseline), 3, 6; end of treatment, 2 months after last dose, every 3 months thereafter for 2 years (up to 46 months) (1 cycle = 28 days)

  13. Number of Hospitalizations Due to Adverse Events (AEs)

    An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not considered related to the study drug.

    Time frame: Day 1 up to 46 months

  14. Percentage of Participants With Adverse Events (AEs)

    An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not considered related to the study drug.

    Time frame: Day 1 up to 46 months

07

Results

Posted Dec 21, 2017

Participant flow

Participant flow — Overall Study
MilestoneObinutuzumab + Bendamustine (BG)
Started102
Completed81
Not completed21
Withdrew: Reason not specified1
Withdrew: Physician decision5
Withdrew: Withdrawal by subject1
Withdrew: Death3
Withdrew: Adverse event11

Outcome measures

PrimaryPercentage of Participants With Complete Response (CR), as Determined by the Investigator Using International Workshop on Chronic Lymphocytic Leukemia National Cancer Institute-Working Group (iwCLL NCI-WG) Guidelines

The CR rate was defined as CR or CR with incomplete blood count recovery (CRi), assessed by the investigator according to iwCLL NCI-WG criteria. The definition of confirmed CR required all of the following criteria as assessed at least 2 months after completion of therapy: peripheral blood lymphocytes \< 4 times 10\^9 cells/L; absence of significant lymphadenopathy, hepatomegaly, or splenomegaly due to CLL involvement; absence of constitutional symptoms; normal complete blood count (CBC) without need for transfusion or exogenous growth factors, as exhibited by neutrophils \>/= 1.5 times 10\^9 cells/L, platelets \> 100 times 10\^9 cells/L, and hemoglobin \> 11.0 g/dL; normocellular BM aspirate with \< 30% lymphocytes; absence of lymphoid nodules; and BM biopsy without CLL activity. Those fulfilling CR criteria but who have persistent anemia, thrombocytopenia, or neutropenia were considered CRi.

Time frame:
2 to 3 months after the last infusion of study treatment (up to approximately 228 to 258 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response (CR), as Determined by the Investigator Using International Workshop on Chronic Lymphocytic Leukemia National Cancer Institute-Working Group (iwCLL NCI-WG) Guidelines
percentage of participantsObinutuzumab + Bendamustine (BG)
Percentage of Participants With Complete Response (CR), as Determined by the Investigator Using International Workshop on Chronic Lymphocytic Leukemia National Cancer Institute-Working Group (iwCLL NCI-WG) Guidelines50.0 (39.9 to 60.1)
SecondaryPercentage of Participants With Objective Response of CR or Partial Response (PR) at the End of Induction Therapy, as Determined by the Investigator Using iwCLL NCI-WG Guidelines

CR is defined in the previous outcome measure. The definition of PR required that the following be documented for minimum 2 months: \>/= 50% decrease in peripheral blood lymphocytes from Baseline; reduction in lymphadenopathy; \>/= 50% reduction in spleen or liver enlargement; and CBC with one of the following without need for transfusion or exogenous growth factors: polymorphonuclear leukocytes \>/= 1.5 times 10\^9 cells/L, platelets \> 100 times 10\^9 cells/L or \>/= 50% improvement from Baseline, or hemoglobin \> 11.0 g/dL or \>/= 50% improvement from Baseline.

Time frame:
2 to 3 months after the last infusion of study treatment (up to approximately 228 to 258 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response of CR or Partial Response (PR) at the End of Induction Therapy, as Determined by the Investigator Using iwCLL NCI-WG Guidelines
percentage of participantsObinutuzumab + Bendamustine (BG)
Percentage of Participants With Objective Response of CR or Partial Response (PR) at the End of Induction Therapy, as Determined by the Investigator Using iwCLL NCI-WG Guidelines89.2 (81.5 to 94.5)
SecondaryDuration of Response Among Participants With Objective Response of CR or PR, as Determined by the Investigator Using iwCLL NCI-WG Guidelines

Duration of response was defined as the time from the first assessment of CR, CRi, PR, or nodular partial response (nPR) to the first documentation of PD or death, whichever occurred first. CR, CRi, and PR are identified in previous outcome measures. Participants with lymphoid nodules who otherwise met CR criteria were considered nPR. Participants with post-baseline response assessments (excluding progressive disease) but with no end-of-induction treatment response available were censored on Day 1, and those with end-of-induction treatment response available but who did not experience death or disease progression before the end of the study were censored on the day of the last available assessment.

Time frame:
From the first assessment of CR, CRi, PR, or nPR (at up to approximately 228 to 258 days) until disease progression, relapse, or death from any cause, whichever occurred first (up to 46 months)
Reported as:
Median · months
Duration of Response Among Participants With Objective Response of CR or PR, as Determined by the Investigator Using iwCLL NCI-WG Guidelines
monthsObinutuzumab + Bendamustine (BG)
Duration of Response Among Participants With Objective Response of CR or PR, as Determined by the Investigator Using iwCLL NCI-WG GuidelinesNA (NA to NA)
SecondaryProgression-Free Survival (PFS), as Determined by the Investigator Using iwCLL NCI-WG Guidelines

PFS was defined as the time from the start of induction treatment (Day 1) to the first occurrence of disease progression, relapse as determined by the investigator using iwCLL NCI WG guidelines, or death (within 28 days after the last dose of study drug), whichever occurred first. Disease progression: at least one of the following: lymphadenopathy; increase in the liver or spleen size by 50% or more or the appearance of hepatomegaly or splenomegaly; an increase in the number of blood lymphocytes by 50% or more with at least 5000 B lymphocytes per microliter; transformation to a more aggressive histology; occurrence of cytopenia (neutropenia, anemia, or thrombocytopenia) attributable to CLL. Relapse: Having achieved CR or PR, but after a period of 6 or more months, having demonstrated evidence of disease progression. Participants who did not experience death or disease progression before the end of the study were censored on the day of the last available assessment.

Time frame:
Day 1 until disease progression, relapse, or death from any cause, whichever occurred first (up to 46 months)
Reported as:
Median · months
Progression-Free Survival (PFS), as Determined by the Investigator Using iwCLL NCI-WG Guidelines
monthsObinutuzumab + Bendamustine (BG)
Progression-Free Survival (PFS), as Determined by the Investigator Using iwCLL NCI-WG GuidelinesNA (35.0 to NA)
SecondaryOverall Survival (OS)

OS was defined as the time from the start of induction treatment to death from any cause. Participants who did not experience death or disease progression before the end of the study were censored on the day of the last available assessment.

Time frame:
Day 1 until death from any cause (up to 46 months)
Reported as:
Median · months
Overall Survival (OS)
monthsObinutuzumab + Bendamustine (BG)
Overall Survival (OS)NA (NA to NA)
SecondaryPercentage of Participants Who Achieved Minimal Residual Disease (MRD)-Negative Status in Bone Marrow at Any Time During the Study

MRD was assessed by 4-color flow cytometry, using iwCLL criteria for MRD negativity (\<1 CLL cell detected in 10,000 leukocytes) in bone marrow aspirate. Flow cytometry provides rapid analysis of multiple characteristics of single cells by using light to count and profile cells in a fluid mixture.

Time frame:
Up to 46 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Minimal Residual Disease (MRD)-Negative Status in Bone Marrow at Any Time During the Study
percentage of participantsObinutuzumab + Bendamustine (BG)
Percentage of Participants Who Achieved Minimal Residual Disease (MRD)-Negative Status in Bone Marrow at Any Time During the Study58.8 (44.2 to 72.4)
SecondaryPercentage of Participants Who Achieved MRD-Negative Status in Peripheral Blood at Any Time During the Study

MRD was assessed by 4-color flow cytometry, using iwCLL criteria for MRD negativity (\<1 CLL cell detected in 10,000 leukocytes) in peripheral blood. Flow cytometry provides rapid analysis of multiple characteristics of single cells by using light to count and profile cells in a fluid mixture.

Time frame:
Baseline up to 46 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved MRD-Negative Status in Peripheral Blood at Any Time During the Study
percentage of participantsObinutuzumab + Bendamustine (BG)
Percentage of Participants Who Achieved MRD-Negative Status in Peripheral Blood at Any Time During the Study83.2 (74.1 to 90.1)
SecondaryTime to MRD-Negative Status in Peripheral Blood

MRD was assessed by 4-color flow cytometry, using iwCLL criteria for MRD negativity if the value is \<10\^-4 (\<1 CLL cell detected in 10,000 leukocytes) in peripheral blood. Flow cytometry provides rapid analysis of multiple characteristics of single cells by using light to count and profile cells in a fluid mixture. Time to MRD-negative status is defined as the time between MRD positivity (\>= 10\^-4) or the time of first dose treatment for patients who were missing MRD status assessment at baseline to the first achievement of MRD negativity in the peripheral blood.

Time frame:
Baseline up to 46 months
Reported as:
Median · months
Time to MRD-Negative Status in Peripheral Blood
monthsObinutuzumab + Bendamustine (BG)
Time to MRD-Negative Status in Peripheral Blood8.2 (7.1 to 10.3)
SecondaryDuration of MRD-Negativity in Peripheral Blood Among Participants Who Achieved MRD-Negative Status

MRD was assessed by 4-color flow cytometry, using iwCLL criteria for MRD negativity (\<1 CLL cell detected in 10,000 leukocytes) in peripheral blood. Flow cytometry provides rapid analysis of multiple characteristics of single cells by using light to count and profile cells in a fluid mixture. Duration of MRD-negativity among patients who achieved MRD negativity in the study is defined as the period between the first occurrence of MRD-negative status and a subsequent MRD-positive status.

Time frame:
Baseline up to 46 months
Reported as:
Median · months
Duration of MRD-Negativity in Peripheral Blood Among Participants Who Achieved MRD-Negative Status
monthsObinutuzumab + Bendamustine (BG)
Duration of MRD-Negativity in Peripheral Blood Among Participants Who Achieved MRD-Negative Status28.9 (23.0 to NA)
SecondaryMinimum Observed Concentration (Ctrough) of Obinutuzumab After Cycle 2

Ctrough is the measured concentration of a drug at the end of a dosing interval at steady state.

Time frame:
Pre-infusion (0 hours) on Day 1 Cycle 3 (1 cycle = 28 days)
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Minimum Observed Concentration (Ctrough) of Obinutuzumab After Cycle 2
nanograms per milliliter (ng/mL)Obinutuzumab + Bendamustine (BG)
Minimum Observed Concentration (Ctrough) of Obinutuzumab After Cycle 2235.92 ± 48.01
SecondaryCtrough of Obinutuzumab After Cycle 4

Ctrough is the measured concentration of a drug at the end of a dosing interval at steady state.

Time frame:
Pre-infusion (0 hours) on Day 1 Cycle 5 (1 cycle = 28 days)
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Ctrough of Obinutuzumab After Cycle 4
nanograms per milliliter (ng/mL)Obinutuzumab + Bendamustine (BG)
Ctrough of Obinutuzumab After Cycle 4264.27 ± 46.45
SecondaryChange From Baseline in the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score

The EORTC QLQ-C30 included global health status, functional scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea/vomiting, and pain) and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Most questions used a 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores were averaged and transformed to 0 - 100 scale, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be a minimally important difference to participants. A positive change from Day 1, Cycle 1 (baseline) indicates improvement. EOT=end of treatment.

Time frame:
Day 1 Cycles 1 (baseline), 3, 6; end of treatment, 2 months after last dose, every 3 months thereafter for 2 years (up to 46 months) (1 cycle = 28 days)
Reported as:
Mean · score on a scale
Change From Baseline in the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score
score on a scaleObinutuzumab + Bendamustine (BG)
Global Health Status (GHS)/QoL: Cycle 34.02 ± 21.540
GHS/QoL: Cycle 65.26 ± 22.478
GHS/QoL: EOT/Early Discontinuation5.17 ± 26.731
GHS/QoL: Response Visit10.98 ± 21.715
GHS/QoL: 3-Month Follow-Up10.25 ± 24.733
GHS/QoL: 6-Month Follow-Up5.68 ± 30.140
GHS/QoL: 9-Month Follow-Up9.26 ± 23.384
GHS/QoL: 12-Month Follow-Up6.43 ± 24.676
GHS/QoL: 15-Month Follow-Up6.57 ± 25.969
GHS/QoL: 18-Month Follow-Up9.84 ± 26.732
GHS/QoL: 21-Month Follow-Up7.60 ± 27.117
GHS/QoL: 24-Month Follow-Up8.91 ± 27.388
GHS/QoL: 27-Month Follow-Up13.26 ± 24.468
GHS/QoL: 30-Month Follow-Up1.66 ± 28.501
Physical Function: Cycle 3-2.46 ± 14.948
Physical Function: Cycle 60.00 ± 12.842
Phys. Function: EOT/Early Discontinuation2.62 ± 15.188
Physical Function: Response Visit3.90 ± 14.705
Physical Function: 3-Month Follow-Up4.14 ± 13.769
Physical Function: 6-Month Follow-Up1.62 ± 17.308
Physical Function: 9-Month Follow-Up4.95 ± 15.208
Physical Function: 12-Month Follow-Up3.00 ± 15.221
Physical Function: 15-Month Follow-Up2.44 ± 17.647
Physical Function: 18-Month Follow-Up1.11 ± 18.589
Physical Function: 21-Month Follow-Up1.37 ± 13.509
Physical Function: 24-Month Follow-Up3.10 ± 14.467
Physical Function: 27-Month Follow-Up4.22 ± 14.057
Physical Function: 30-Month Follow-Up5.34 ± 8.691
Role Function: Cycle 36.01 ± 24.775
Role Function: Cycle 64.11 ± 27.193
Role Function: EOT/Early Discontinuation10.55 ± 27.108
Role Function: Response Visit13.14 ± 29.106
Role Function: 3-Month Follow-Up14.87 ± 28.210
Role Function: 6-Month Follow-Up10.86 ± 29.453
Role Function: 9-Month Follow-Up15.51 ± 27.312
Role Function: 12-Month Follow-Up10.63 ± 28.591
Role Function: 15-Month Follow-Up12.68 ± 30.920
Role Function: 18-Month Follow-Up10.88 ± 33.352
Role Function: 21-Month Follow-Up10.95 ± 28.656
Role Function: 24-Month Follow-Up11.49 ± 30.780
Role Function: 27-Month Follow-Up14.97 ± 30.285
Role Function: 30-Month Follow-Up-13.33 ± 36.132
Emotional Function: Cycle 37.91 ± 18.092
Emotional Function: Cycle 66.29 ± 18.304
Emotional Function: EOT/Early Discont.9.60 ± 18.302
Emotional Function: Response Visit9.12 ± 18.663
Emotional Function: 3-Month Follow-Up8.11 ± 18.861
Emotional Function: 6-Month Follow-Up6.94 ± 19.424
Emotional Function: 9-Month Follow-Up11.00 ± 13.402
Emotional Function: 12-Month Follow-Up7.81 ± 18.793
Emotional Function: 15-Month Follow-Up6.34 ± 23.883
Emotional Function: 18-Month Follow-Up5.75 ± 22.214
Emotional Function: 21-Month Follow-Up7.11 ± 19.597
Emotional Function: 24-Month Follow-Up9.77 ± 19.380
Emotional Function: 27-Month Follow-Up10.15 ± 18.845
Emotional Function: 30-Month Follow-Up8.33 ± 15.591
Cognitive Function: Cycle 32.55 ± 22.640
Cognitive Function: Cycle 6-1.75 ± 25.177
Cognitive Function: EOT/Early Discont.0.42 ± 17.697
Cognitive Function: Response Visit2.74 ± 20.387
Cognitive Function: 3-Month Follow-Up2.25 ± 17.946
Cognitive Function: 6-Month Follow-Up1.77 ± 23.043
Cognitive Function: 9-Month Follow-Up6.02 ± 17.312
Cognitive Function: 12-Month Follow-Up1.48 ± 19.646
Cognitive Function: 15-Month Follow-Up2.11 ± 20.878
Cognitive Function: 18-Month Follow-Up2.55 ± 20.105
Cognitive Function: 21-Month Follow-Up3.19 ± 20.815
Cognitive Function: 24-Month Follow-Up4.02 ± 18.550
Cognitive Function: 27-Month Follow-Up1.70 ± 16.401
Cognitive Function: 30-Month Follow-Up-3.33 ± 21.726
Social Function: Cycle 3-2.35 ± 21.386
Social Function: Cycle 6-4.17 ± 23.590
Social Function: EOT/Early Discontinuation2.53 ± 23.279
Social Function: Response Visit5.69 ± 24.874
Social Function: 3-Month Follow-Up5.41 ± 23.587
Social Function: 6-Month Follow-Up-0.25 ± 26.872
Social Function: 9-Month Follow-Up8.10 ± 19.579
Social Function: 12-Month Follow-Up2.74 ± 24.667
Social Function: 15-Month Follow-Up3.76 ± 25.696
Social Function: 18-Month Follow-Up3.70 ± 27.296
Social Function: 21-Month Follow-Up2.70 ± 26.952
Social Function: 24-Month Follow-Up5.46 ± 21.032
Social Function: 27-Month Follow-Up7.48 ± 23.088
Social Function: 30-Month Follow-Up-10.00 ± 30.277
Fatigue: Cycle 3-4.01 ± 25.433
Fatigue: Cycle 6-5.48 ± 24.558
Fatigue: EOT/Early Discontinuation-11.67 ± 24.324
Fatigue: Response Visit-16.34 ± 25.291
Fatigue: 3-Month Follow-Up-15.92 ± 24.266
Fatigue: 6-Month Follow-Up-13.64 ± 24.171
Fatigue: 9-Month Follow-Up-17.28 ± 23.947
Fatigue: 12-Month Follow-Up-13.12 ± 24.261
Fatigue: 15-Month Follow-Up-11.27 ± 25.441
Fatigue: 18-Month Follow-Up-13.43 ± 24.946
Fatigue: 21-Month Follow-Up-13.07 ± 22.465
Fatigue: 24-Month Follow-Up-14.37 ± 21.429
Fatigue: 27-Month Follow-Up-14.51 ± 23.373
Fatigue: 30-Month Follow-Up-2.22 ± 16.480
Nausea/Vomiting: Cycle 32.33 ± 16.990
Nausea/Vomiting: Cycle 63.68 ± 14.210
Nausea/Vomiting: EOT/Early Discontinuation2.32 ± 13.273
Nausea/Vomiting: Response Visit-0.39 ± 15.209
Nausea/Vomiting: 3-Month Follow-Up-1.58 ± 9.624
Nausea/Vomiting: 6-Month Follow-Up-1.26 ± 12.164
Nausea/Vomiting: 9-Month Follow-Up-0.23 ± 16.428
Nausea/Vomiting: 12-Month Follow-Up-1.04 ± 13.350
Nausea/Vomiting: 15-Month Follow-Up0.70 ± 13.926
Nausea/Vomiting: 18-Month Follow-Up-0.23 ± 13.267
Nausea/Vomiting: 21-Month Follow-Up-1.72 ± 13.240
Nausea/Vomiting: 24-Month Follow-Up-2.01 ± 14.333
Nausea/Vomiting: 27-Month Follow-Up-1.70 ± 14.925
Nausea/Vomiting: 30-Month Follow-Up10.00 ± 14.910
Pain: Cycle 3-3.68 ± 17.969
Pain: Cycle 60.65 ± 26.826
Pain: EOT/Early Discontinuation-1.90 ± 21.012
Pain: Response Visit-4.90 ± 20.865
Pain: 3-Month Follow-Up-1.80 ± 17.570
Pain: 6-Month Follow-Up-1.52 ± 20.615
Pain: 9-Month Follow-Up-0.69 ± 20.448
Pain: 12-Month Follow-Up-0.21 ± 24.947
Pain: 15-Month Follow-Up0.94 ± 26.709
Pain: 18-Month Follow-Up-0.46 ± 25.326
Pain: 21-Month Follow-Up-0.00 ± 23.035
Pain: 24-Month Follow-Up-2.59 ± 19.447
Pain: 27-Month Follow-Up-5.44 ± 26.654
Pain: 30-Month Follow-Up6.67 ± 48.015
Dyspnoea: Cycle 30.39 ± 27.294
Dyspnoea: Cycle 6-1.73 ± 25.874
Dyspnoea: EOT/Early Discontinuation-5.91 ± 31.013
Dyspnoea: Response Visit-5.88 ± 30.069
Dyspnoea: 3-Month Follow-Up-9.46 ± 27.872
Dyspnoea: 6-Month Follow-Up-8.08 ± 27.463
Dyspnoea: 9-Month Follow-Up-7.87 ± 29.334
Dyspnoea: 12-Month Follow-Up-5.83 ± 30.824
Dyspnoea: 15-Month Follow-Up-5.63 ± 29.270
Dyspnoea: 18-Month Follow-Up-7.87 ± 28.796
Dyspnoea: 21-Month Follow-Up-8.82 ± 27.289
Dyspnoea: 24-Month Follow-Up-7.47 ± 28.642
Dyspnoea: 27-Month Follow-Up-11.56 ± 31.587
Dyspnoea: 30-Month Follow-Up-20.00 ± 18.256
Insomnia: Cycle 3-6.59 ± 27.450
Insomnia: Cycle 6-9.09 ± 24.565
Insomnia: EOT/Early Discontinuation-9.70 ± 25.684
Insomnia: Response Visit-10.98 ± 28.354
Insomnia: 3-Month Follow-Up-9.46 ± 25.596
Insomnia: 6-Month Follow-Up-14.65 ± 29.312
Insomnia: 9-Month Follow-Up-12.50 ± 29.306
Insomnia: 12-Month Follow-Up-9.70 ± 31.193
Insomnia: 15-Month Follow-Up-13.61 ± 30.643
Insomnia: 18-Month Follow-Up-8.80 ± 30.640
Insomnia: 21-Month Follow-Up-7.84 ± 29.991
Insomnia: 24-Month Follow-Up-14.37 ± 28.691
Insomnia: 27-Month Follow-Up-10.20 ± 36.136
Insomnia: 30-Month Follow-Up-6.67 ± 49.443
Appetite Loss: Cycle 3-2.71 ± 20.589
Appetite Loss: Cycle 60.00 ± 26.490
Appetite Loss: EOT/Early Discontinuation-3.80 ± 18.480
Appetite Loss: Response Visit-7.06 ± 21.878
Appetite Loss: 3-Month Follow-Up-9.91 ± 18.896
Appetite Loss: 6-Month Follow-Up-9.60 ± 18.270
Appetite Loss: 9-Month Follow-Up-10.80 ± 22.378
Appetite Loss: 12-Month Follow-Up-8.75 ± 20.364
Appetite Loss: 15-Month Follow-Up-6.57 ± 24.312
Appetite Loss: 18-Month Follow-Up-7.41 ± 19.557
Appetite Loss: 21-Month Follow-Up-4.90 ± 23.928
Appetite Loss: 24-Month Follow-Up-7.47 ± 20.748
Appetite Loss: 27-Month Follow-Up-8.16 ± 19.872
Appetite Loss: 30-Month Follow-Up-6.67 ± 14.906
Constipation: Cycle 33.92 ± 34.661
Constipation: Cycle 6-0.00 ± 24.944
Constipation: EOT/Early Discontinuation-4.27 ± 18.105
Constipation: Response Visit-4.36 ± 24.147
Constipation: 3-Month Follow-Up-5.02 ± 18.979
Constipation: 6-Month Follow-Up-6.06 ± 19.312
Constipation: 9-Month Follow-Up-5.16 ± 24.975
Constipation: 12-Month Follow-Up-3.80 ± 25.028
Constipation: 15-Month Follow-Up-3.76 ± 19.147
Constipation: 18-Month Follow-Up-0.46 ± 24.059
Constipation: 21-Month Follow-Up-2.45 ± 22.538
Constipation: 24-Month Follow-Up-6.32 ± 21.134
Constipation: 27-Month Follow-Up-6.80 ± 21.494
Constipation: 30-Month Follow-Up0.00 ± 0.000
Diarrhoea: Cycle 31.18 ± 21.483
Diarrhoea: Cycle 64.82 ± 24.767
Diarrhoea: EOT/Early Discontinuation4.64 ± 29.105
Diarrhoea: Response Visit2.75 ± 24.780
Diarrhoea: 3-Month Follow-Up-2.25 ± 20.886
Diarrhoea: 6-Month Follow-Up-1.01 ± 24.085
Diarrhoea: 9-Month Follow-Up3.24 ± 23.174
Diarrhoea: 12-Month Follow-Up-0.43 ± 21.816
Diarrhoea: 15-Month Follow-Up0.00 ± 25.197
Diarrhoea: 18-Month Follow-Up-2.78 ± 26.090
Diarrhoea: 21-Month Follow-Up3.43 ± 28.875
Diarrhoea: 24-Month Follow-Up-0.57 ± 22.067
Diarrhoea: 27-Month Follow-Up1.36 ± 21.471
Diarrhoea: 30-Month Follow-Up0.00 ± 23.568
Financial Difficulty: Cycle 30.78 ± 25.186
Financial Difficulty: Cycle 6-2.19 ± 27.934
Financial Difficulty: EOT/Early Discont.-1.27 ± 26.923
Financial Difficulty: Response Visit-3.53 ± 29.107
Financial Difficulty: 3-Month Follow-Up-5.86 ± 27.784
Financial Difficulty: 6-Month Follow-Up-7.18 ± 27.947
Financial Difficulty: 9-Month Follow-Up-7.04 ± 26.972
Financial Difficulty: 12-Month Follow-Up-3.80 ± 30.188
Financial Difficulty: 15-Month Follow-Up-8.45 ± 29.125
Financial Difficulty: 18-Month Follow-Up-6.02 ± 31.313
Financial Difficulty: 21-Month Follow-Up-6.86 ± 25.471
Financial Difficulty: 24-Month Follow-Up-7.47 ± 26.523
Financial Difficulty: 27-Month Follow-Up-11.56 ± 31.587
Financial Difficulty: 30-Month Follow-Up-13.33 ± 29.813
SecondaryChange From Baseline in the EORTC Quality of Life Questionnaire-Chronic Lymphocytic Leukemia 16 (QLQ-CLL16) Score

The EORTC Quality of Life Questionnaire-Chronic Lymphocytic Leukemia 16 (QLQ-CLL16) module included assessments of fatigue, treatment side effects, disease symptoms, infection, social activities, and future health worries. Final scores are transformed such that they range from 0 - 100, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be a minimally important difference to participants. A positive change from Day 1, Cycle 1 (baseline) indicates improvement. EOT=end of treatment.

Time frame:
Day 1 Cycles 1 (baseline), 3, 6; end of treatment, 2 months after last dose, every 3 months thereafter for 2 years (up to 46 months) (1 cycle = 28 days)
Reported as:
Mean · score on a scale
Change From Baseline in the EORTC Quality of Life Questionnaire-Chronic Lymphocytic Leukemia 16 (QLQ-CLL16) Score
score on a scaleObinutuzumab + Bendamustine (BG)
Fatigue: Cycle 3-12.02 ± 26.892
Fatigue: Cycle 6-10.17 ± 26.373
Fatigue: EOT/Early Discontinuation-12.87 ± 30.306
Fatigue: Response Visit-21.23 ± 30.759
Fatigue: 3-Month Follow-Up-20.04 ± 29.323
Fatigue: 6-Month Follow-Up-17.44 ± 25.418
Fatigue: 9-Month Follow-Up-22.77 ± 27.780
Fatigue: 12-Month Follow-Up-17.32 ± 25.569
Fatigue: 15-Month Follow-Up-14.52 ± 30.153
Fatigue: 18-Month Follow-Up-15.49 ± 30.122
Fatigue: 21-Month Follow-Up-16.42 ± 28.646
Fatigue: 24-Month Follow-Up-24.70 ± 25.621
Fatigue: 27-Month Follow-Up-19.56 ± 26.597
Fatigue: 30-Month Follow-Up-6.67 ± 53.489
Side Effects: Cycle 31.52 ± 12.019
Side Effects: Cycle 60.07 ± 16.072
Side Effects: EOT/Early Discontinuation-0.67 ± 16.357
Side Effects: Response Visit-2.08 ± 14.520
Side Effects: 3-Month Follow-Up-3.30 ± 12.904
Side Effects: 6-Month Follow-Up-2.61 ± 15.182
Side Effects: 9-Month Follow-Up-3.36 ± 14.548
Side Effects: 12-Month Follow-Up-2.27 ± 14.841
Side Effects: 15-Month Follow-Up-3.17 ± 14.355
Side Effects: 18-Month Follow-Up-4.54 ± 14.813
Side Effects: 21-Month Follow-Up-1.66 ± 16.277
Side Effects: 24-Month Follow-Up-3.08 ± 13.699
Side Effects: 27-Month Follow-Up-2.96 ± 14.434
Side Effects: 30-Month Follow-Up-11.67 ± 4.566
Disease Symptoms: Cycle 3-9.56 ± 18.196
Disease Symptoms: Cycle 6-8.30 ± 20.039
Disease Symptoms: EOT/Early Discontinuation-10.02 ± 20.371
Disease Symptoms: Response Visit-12.67 ± 18.019
Disease Symptoms: 3-Month Follow-Up-12.20 ± 18.630
Disease Symptoms: 6-Month Follow-Up-10.13 ± 16.699
Disease Symptoms: 9-Month Follow-Up-12.28 ± 18.478
Disease Symptoms: 12-Month Follow-Up-8.62 ± 18.297
Disease Symptoms: 15-Month Follow-Up-9.05 ± 19.284
Disease Symptoms: 18-Month Follow-Up-10.41 ± 20.632
Disease Symptoms: 21-Month Follow-Up-9.16 ± 21.398
Disease Symptoms: 24-Month Follow-Up-10.71 ± 17.675
Disease Symptoms: 27-Month Follow-Up-11.41 ± 19.904
Disease Symptoms: 30-Month Follow-Up-5.00 ± 20.917
Infection: Cycle 36.20 ± 18.182
Infection: Cycle 64.11 ± 16.406
Infection: EOT/Early Discontinuation1.65 ± 15.199
Infection: Response Visit0.76 ± 17.528
Infection: 3-Month Follow-Up2.59 ± 20.779
Infection: 6-Month Follow-Up3.46 ± 23.611
Infection: 9-Month Follow-Up1.45 ± 17.135
Infection: 12-Month Follow-Up4.42 ± 22.269
Infection: 15-Month Follow-Up2.86 ± 19.602
Infection: 18-Month Follow-Up2.62 ± 22.532
Infection: 21-Month Follow-Up2.78 ± 18.502
Infection: 24-Month Follow-Up0.89 ± 15.134
Infection: 27-Month Follow-Up1.45 ± 14.731
Infection: 30-Month Follow-Up-5.00 ± 9.502
Social Activities: Cycle 3-3.92 ± 28.827
Social Activities: Cycle 6-3.95 ± 34.412
Social Activities: EOT/Early Discont.-6.41 ± 33.141
Social Activities: Response Visit-9.24 ± 33.054
Social Activities: 3-Month Follow-Up-11.87 ± 27.983
Social Activities: 6-Month Follow-Up-4.69 ± 33.527
Social Activities: 9-Month Follow-Up-13.33 ± 28.033
Social Activities: 12-Month Follow-Up-7.89 ± 27.145
Social Activities: 15-Month Follow-Up-6.76 ± 34.099
Social Activities: 18-Month Follow-Up-5.71 ± 31.583
Social Activities: 21-Month Follow-Up-4.55 ± 32.495
Social Activities: 24-Month Follow-Up-11.51 ± 28.845
Social Activities: 27-Month Follow-Up-9.42 ± 29.534
Social Activities: 30-Month Follow-Up0.00 ± 66.668
Future Health Worries: Cycle 3-20.08 ± 30.329
Future Health Worries: Cycle 6-14.04 ± 29.946
Future Health Worries: EOT/Early Discont.-18.57 ± 32.794
Future Health Worries: Response Visit-20.24 ± 28.351
Future Health Worries: 3-Month Follow-Up-25.11 ± 29.805
Future Health Worries: 6-Month Follow-Up-17.44 ± 30.680
Future Health Worries: 9-Month Follow-Up-23.47 ± 27.253
Future Health Worries: 12-Month Follow-Up-19.23 ± 26.053
Future Health Worries: 15-Month Follow-Up-17.14 ± 33.929
Future Health Worries: 18-Month Follow-Up-19.72 ± 34.540
Future Health Worries: 21-Month Follow-Up-21.21 ± 27.820
Future Health Worries: 24-Month Follow-Up-21.82 ± 30.911
Future Health Worries: 27-Month Follow-Up-25.36 ± 31.572
Future Health Worries: 30-Month Follow-Up-6.67 ± 27.892
SecondaryNumber of Hospitalizations Due to Adverse Events (AEs)

An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not considered related to the study drug.

Time frame:
Day 1 up to 46 months
Reported as:
Mean · hospitalizations
Number of Hospitalizations Due to Adverse Events (AEs)
hospitalizationsObinutuzumab + Bendamustine (BG)
Number of Hospitalizations Due to Adverse Events (AEs)1.43 ± 0.634
SecondaryPercentage of Participants With Adverse Events (AEs)

An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not considered related to the study drug.

Time frame:
Day 1 up to 46 months
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs)
percentage of participantsObinutuzumab + Bendamustine (BG)
Percentage of Participants With Adverse Events (AEs)100

Adverse events

Collected over Day 1 up to 46 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Obinutuzumab + Bendamustine (BG)7/102 (6.9%)31/102 (30.4%)101/102 (99%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventObinutuzumab + Bendamustine (BG)
PneumoniaInfections and infestations7/102
PyrexiaGeneral disorders5/102
Febrile neutropeniaBlood and lymphatic system disorders4/102
Tumour lysis syndromeMetabolism and nutrition disorders4/102
DehydrationMetabolism and nutrition disorders3/102
Urinary tract infectionInfections and infestations2/102
Infusion related reactionInjury, poisoning and procedural complications2/102
HypotensionVascular disorders2/102
AnaemiaBlood and lymphatic system disorders1/102
Cardiac arrestCardiac disorders1/102
Most frequent other events
Showing 10 of 45
Most frequent other events
EventObinutuzumab + Bendamustine (BG)
Infusion related reactionInjury, poisoning and procedural complications76/102
NauseaGastrointestinal disorders54/102
NeutropeniaBlood and lymphatic system disorders36/102
FatigueGeneral disorders36/102
PyrexiaGeneral disorders35/102
RashSkin and subcutaneous tissue disorders28/102
ConstipationGastrointestinal disorders27/102
DiarrhoeaGastrointestinal disorders24/102
VomitingGastrointestinal disorders21/102
ThrombocytopeniaBlood and lymphatic system disorders20/102

Baseline characteristics

Age, Continuous
Age, Continuous(years)Obinutuzumab + Bendamustine (BG)
Mean62.5 ± 10.79
Sex: Female, Male
Sex: Female, Male(Participants)Obinutuzumab + Bendamustine (BG)
Female32
Male70
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Obinutuzumab + Bendamustine (BG)
Hispanic or Latino1
Not Hispanic or Latino97
Unknown or Not Reported4
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Obinutuzumab + Bendamustine (BG)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White98
More than one race0
Unknown or Not Reported2
08

Study locations

26 sites
  • Clearview Cancer Institute
    Huntsville, Alabama 35805, United States
  • Southern Cancer Center - Mobile
    Mobile, Alabama 36608, United States
  • Ironwood Cancer TX & Rsch Ctrs
    Chandler, Arizona 85224, United States
  • Arizona Oncology Associates, PC - HAL
    Tempe, Arizona 85284, United States
  • Arizona Oncology Associates, PC - HOPE
    Tucson, Arizona 85704, United States
  • Highlands Oncology Group
    Fayetteville, Arkansas 72703, United States
  • Rocky Mountain Cancer Center - Aurora
    Aurora, Colorado 80012, United States
  • Cancer Care and Hematology
    Fort Collins, Colorado 80528, United States
  • Piedmont Cancer Institute, PC
    Atlanta, Georgia 30318, United States
  • Northwest Georgia Oncology Centers PC - Marietta
    Marietta, Georgia 30060, United States
  • Cancer Care & Hematology; Specialists of Chicagoland
    Niles, Illinois 60714, United States
  • Fort Wayne Med Oncology & Hematology Inc
    Fort Wayne, Indiana 46845, United States
  • Center For Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
  • Regional Cancer Care Associates LLC - Morristown
    Morristown, New Jersey 07962, United States
  • San Juan Oncology Associates
    Farmington, New Mexico 87401, United States
  • Stony Brook University Hospital
    Stony Brook, New York 11794, United States
  • Northwest Cancer Specialists - Portland (N Broadway)
    Portland, Oregon 97227, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Willamette Valley Cancer Insitute and Research Center
    Springfield, Oregon 97477, United States
  • Texas Oncology-Arlington
    Arlington, Texas 76012, United States
  • Texas Oncology-Tyler
    Irving, Texas 75063, United States
  • Joe Arrington Cancer Research & Treatment Center
    Lubbock, Texas 79410, United States
  • Cancer Care Centers of South Texas-HOAST - San Antonio
    New Braunfels, Texas 78130, United States
  • Northern Utah Associates
    Ogden, Utah 84403, United States
  • Virginia Cancer Specialists, PC
    Fairfax, Virginia 22031, United States
  • Yakima Valley Memorial Hospital/North Star Lodge
    Yakima, Washington 98902, United States
09

References and documents

Publications

  • Sharman JP, Burke JM, Yimer HA, Boxer MA, Babu S, Li J, Mun Y, Danilov AV; GIBB study investigators. Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2021 Apr;62(4):791-800. doi: 10.1080/10428194.2020.1850719. Epub 2020 Nov 26. PubMed 33243049 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Nov 2016, 19 months.

Results were first posted in Dec 2017, 1 year 1 month after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 19 months is below that.

Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2014
First posted
Dec 19, 2014
StartActual
Mar 31, 2015
Primary completionActual
Nov 7, 2016
CompletionActual
Feb 6, 2019
Results first posted
Dec 21, 2017
Last update
Feb 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02320487
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Dec 19, 2014
Start date
Mar 31, 2015
Primary completion
Nov 7, 2016
Completion
Feb 6, 2019
Results posted
Dec 21, 2017
Last update
Feb 11, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bendamustine · Obinutuzumab

Start the discussion